Andrea Tan's Stock Ratings

Goldman Sachs Analyst

Andrea Tan is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/31/2024

Overall Average Return

-2.29%

Smart Score

47.7%

Overall Average Return Percentile

32nd

Number of Ratings

36
Buy NowGet Alert
05/29/2024INSMBuy Now
Insmed
$55.3033.82%$49 → $74MaintainsBuyGet Alert
05/16/2024SGMTBuy Now
Sagimet Biosciences
$5.44322.8%$27 → $23MaintainsBuyGet Alert
05/15/2024INSMBuy Now
Insmed
$55.30-11.39%$40 → $49MaintainsBuyGet Alert
03/26/2024SGMTBuy Now
Sagimet Biosciences
$5.44396.33%$37 → $27MaintainsBuyGet Alert
02/29/2024IOVABuy Now
Iovance Biotherapeutics
$8.92135.43%$19 → $21MaintainsBuyGet Alert
02/29/2024TARSBuy Now
Tarsus Pharmaceuticals
$32.96-8.98%$19 → $30MaintainsNeutralGet Alert
02/27/2024DAWNBuy Now
Day One Biopharmaceutical
$13.44227.38%$50 → $44MaintainsBuyGet Alert
02/21/2024IOVABuy Now
Iovance Biotherapeutics
$8.92113%$13 → $19MaintainsBuyGet Alert
02/20/2024IOVABuy Now
Iovance Biotherapeutics
$8.92113%$13 → $19MaintainsBuyGet Alert
01/23/2024SGMTBuy Now
Sagimet Biosciences
$5.44580.16%$30 → $37MaintainsBuyGet Alert
12/11/2023KODBuy Now
Kodiak Sciences
$3.18-37.11% → $2Reinstates → SellGet Alert
11/20/2023IMGNBuy Now
Immunogen
—— → $17Initiates → NeutralGet Alert
11/20/2023KRYSBuy Now
Krystal Biotech
$160.05-0.03% → $160Initiates → BuyGet Alert
11/20/2023IOVABuy Now
Iovance Biotherapeutics
$8.9234.53% → $12Initiates → BuyGet Alert
11/20/2023TARSBuy Now
Tarsus Pharmaceuticals
$32.96-42.35% → $19Initiates → NeutralGet Alert
08/08/2023DAWNBuy Now
Day One Biopharmaceutical
$13.44301.79%$63 → $54MaintainsBuyGet Alert
08/08/2023SGMTBuy Now
Sagimet Biosciences
$5.44506.63% → $33Initiates → BuyGet Alert
08/04/2023ABCLBuy Now
AbCellera Biologics
$4.12482.52%$27 → $24MaintainsBuyGet Alert
01/09/2023INSMBuy Now
Insmed
$55.30-29.48%$44 → $39MaintainsBuyGet Alert
01/09/2023FATEBuy Now
Fate Therapeutics
$3.727.53%$10 → $4MaintainsSellGet Alert
01/09/2023DAWNBuy Now
Day One Biopharmaceutical
$13.44361.31%$45 → $62MaintainsBuyGet Alert
12/20/2022MDGLBuy Now
Madrigal Pharmaceuticals
$236.1658.79%$178 → $375MaintainsBuyGet Alert
12/15/2022ABCLBuy Now
AbCellera Biologics
$4.12628.16% → $30Initiates → BuyGet Alert
12/15/2022VERVBuy Now
Verve Therapeutics
$5.19150.48% → $13Initiates → SellGet Alert
12/15/2022FATEBuy Now
Fate Therapeutics
$3.72168.82% → $10Initiates → SellGet Alert
12/05/2022DAWNBuy Now
Day One Biopharmaceutical
$13.44234.82% → $45Initiates → BuyGet Alert
11/07/2022CDAKBuy Now
Codiak BioSciences
——$2 → $1.4MaintainsNeutralGet Alert
10/14/2022RLMDBuy Now
Relmada Therapeutics
$3.02164.9% → $8DowngradeBuy → NeutralGet Alert
09/23/2022RLMDBuy Now
Relmada Therapeutics
$3.022582.12%$49 → $81MaintainsBuyGet Alert
09/01/2022CDAKBuy Now
Codiak BioSciences
——$6 → $2DowngradeBuy → NeutralGet Alert

Recent Analyst Stock Rating News

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Dell To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Analyst Ratings For Tarsus Pharmaceuticals
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. Madrigal Pharmaceuticals shares jumped 268.1% to close at $234.83 on Monday and gained 4.4% to trade at $245.26 on Tuesday.
Cannabis Movers & Shakers: Columbia Care, Affinor Growers, Open Book Extracts, Trait Biosciences, WM Technology, CBD Health Club, MedMen, TGOD, Cann American
Columbia Care Welcomes Former Green Leaf CEO And Co-Founder Philip Goldberg To Board
Every Member Of Trump's 'Great American Economic Revival' Industry Groups
President Donald Trump annnounced a lengthy list of "Great American Economic Revival" industry groups Tuesday that he said will advise the White House on reopening the economy after the shutdown necessitated by the coronavirus pandemic. 
The 50 Tiniest Dog Breeds
UPDATE: Goldman Names 266 Managing Directors
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free